Cost-effectiveness analyses of hepatitis A vaccine: A systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies

PharmacoEconomics

Volumn 26, Issue 1, 2008, Pages 17-32

  Anonychuk, Andrea M ^a,b,c   Tricco, Andrea C ^d,e   Bauch, Chris T ^f   Pham, Ba ^a,c,d   Gilca, Vladimir ^g,h   Duval, Bernard ^g,h   John Baptiste, Ava ^a,c,i   Woo, Gloria ^a,c   Krahn, Murray ^a,c,i,j  

^a UNIVERSITY OF TORONTO   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF GUELPH   (Canada)

^g INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

Cost effectiveness; Cost utility; Hepatitis A vaccine, therapeutic use; Hepatitis A, prevention; Modelling

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE;

ANTIBODY SCREENING; ARMY; CITATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA SYNTHESIS; DRUG COST; EVALUATION; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HEPATITIS A; HEPATITIS B; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; MASS IMMUNIZATION; METHODOLOGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 37549042743     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826010-00003     Document Type: Review

References (72)

1. Di Giammarino L, Dienstag JL. Hepatitis A: the price of progress. N Engl J Med 2005 Sep 1; 353 (9): 944-6
2. Scheifele DW, Ochnio J. Hepatitis A vaccine: is it being used to best advantage? CMAJ 2002 Jul 9; 167 (1): 44-5
3. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005 Jul 13; 294 (2): 202-10
4. Dominguez A, Bruguera M, Plans P, et al. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization. J Med Virol 2004 Jun; 73 (2): 172-6
5. Germinario C, Lopalco PL, Chirona M, et al. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 2000 Feb 18; 18 Suppl. 1: S83-5
6. Jenson HB. The changing picture of hepatitis A in the United States. Curr Opin Pediatr 2004 Feb; 16 (1): 89-93
7. Navas E, Salleras L, Gisbert R, et al. Efficiency of the incorporation of the hepatitis a vaccine as a combined A + B vaccine to the hepatitis B vaccination programme of preadolescents in schools. Vaccine 2005; 23 (17-18): 2185-9
8. Health Canada. Canadian immunization guide. 6th ed. Ottawa: Canadian Medical Association, 2002
9. Andre FE. Universal mass vaccination against hepatitis A. Curr Top Microbiol Immunol 2006; 304: 95-114
10. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006; 28: 101-11
11. Krahn M, Remis R, Hogg R, et al. Universal hepatitis A vaccination for adolescents and children in Canada: a cost effectiveness analysis [online]. Available from URL: http://www.phacaspc.gc.ca/publicat/ccdr-rmtc/05vol31/ dr3115eb.html [Accessed 2007 Oct 31]
12. Mason J, Eccles M, Freemantle N, et al. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy 1999; 47 (1): 37-52
13. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329 (7459): 224-7
14. Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20 (1): 1-7
15. Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 2000 Jun 20; 132 (12): 964-72
16. Davies L, Coyle D, Drummond M. Current status of economic appraisal of health technology in the European Community: report of the network. The EC Network on the Methodology of Economic Appraisal of Health Technology. Soc Sci Med 1994; 38 (12): 1601-7
17. Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the UK. Soc Sci Med 1997; 45 (4): 583-95
18. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999 Dec 15; 18 (23): 3263-82
19. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003 Jan; 23 (1): 76-82
20. Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004 Oct; 22 (31-32): 4342-50
21. Chen H, Bauch C, Foty R, et al. Use of catalytic modeling to estimate hepatitis A incidence in a low endemicity country: implications for modeling immunization policies [abstract]. Available from URL: http://smdm.confex.com/ smdm/2004ga/techprogram/P1609.htm [Accessed 2007 Oct 31]
22. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002 May; 109 (5): 839-45
23. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 Mar 25; 332 (7543): 699-703
24. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977 Jun; 33 (2): 363-74
25. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP) [online]. Available from URL: http://www.oecd.org/std/ppp/ [Accessed 2007 Jan 1]
26. US Department of Labor. US labor statistics data [online]. Available from URL: http://data.bls.gov/PDQ/servlet/SurveyOutputServlet [Accessed 2007 Jan 1]
27. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004 Feb; 7 (1): 43-9
28. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992 Feb 15; 146 (4): 473-81
29. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998 Oct; 13 (10): 716-7
30. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355-71
31. Arguedas MR, Heudebert GR, Fallon MB, et al. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002 Mar; 97 (3): 721-8
32. Arnal JM, Frisa O, Garuz R, et al. Cost effectiveness of hepatitis A virus immunisation in Spain. Pharmacoeconomics 1997; (3): 361-73
33. Bauch CT, Anonychuk AM, Pham BZ, et al. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007; 25 (51): 8536-48
34. Buma AH, Beutels P, Van DP, et al. An economic evaluation of hepatitis A vaccination in Dutch military personnel. Mil Med 1998 Aug; 163 (8): 564-7
35. Chodick G, Lerman Y, Wood F, et al. Cost-utility analysis of hepatitis a prevention among health-care workers in Israel. J Occup Environ Med 2002; 44 (2): 109-15
36. Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology 1999; (2): 548-52
37. Demicheli V, Carniglia E, Fucci S. The use of hepatitis A vaccination in Italy: an economic evaluation. Vaccine 2003 Jun 2; 21 (19-20): 2250-7
38. Diel R, Rappenhoner B, Schneider S. Cost-effectiveness of hepatitis A immunization of children and adolescents in Germany. Hepac Health Econ Prev Care 2001; 2 (3): 96-103
39. Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Ped Adolesc Med 2000; 154 (8): 763-70
40. Jacobs RJ, Grover SF, Meyerhoff AS, et al. Cost effectiveness of vaccinating food service workers against hepatitis A infection. J Food Protect 2000 Jun; 63 (6): 768-74
41. Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97 (2): 427-34
42. Jacobs RJ, Greenberg DP, Koff RS, et al. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 2003; 22 (10): 904-14
43. Jacobs RJ, Meyerhoff AS. Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics. Sex Transm Dis 2003 Nov; 30 (11): 859-65
44. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 2003 May; 51 (6): 227-36
45. Jacobs RJ, Gibson GA, Meyerhoff AS. Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the Western United States. Infect Control Hosp Epidemiol 2004; 25 (7): 563-9
46. Jacobs RJ, Rosenthal P, Meyerhoff AS. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates. Vaccine 2004 Mar 12; 22 (9-10): 1241-8
47. Jefferson TO, Behrens RH, Demicheli V. Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine 1994; 12 (15): 1379-83
48. Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000; 31 (4): 834-9
49. O'Connor JB, Imperiale TF, Singer ME. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatology 1999; 30 (4): 1077-81
50. Pechevis M, Khoshnood B, Buteau L, et al. Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection. Vaccine 2003; 21 (25-26): 3556-64
51. Postma MJ, Bos JM, Beutels P, et al. Pharmaco-economic evaluation of targeted hepatitis a vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 2004; 22 (15-16): 1862-7
52. Rajan E, Shattock AG, Fielding JF. Cost-effective analysis of hepatitis A prevention in Ireland. Am J Gastroenterol 2000; 95 (1): 223-6
53. Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007 Jan; 119 (1): e12-21
54. Severo CA, Fagnani F, Lafuma A. Cost effectiveness of hepatitis A prevention in France. Pharmacoeconomics 1995; 8 (1): 46-61
55. Smith S, Weber S, Wiblin T, et al. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect Control Hosp Epidemiol 1997 Oct; 18 (10): 688-91
56. Szucs T. Cost-effectiveness of hepatitis A and B vaccination programme in Germany. Vaccine 2000; 18 (S1): S86-9
57. Tormans G, Van DP, Van DE. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine 1992; 10 (S1): S88-92
58. Valenzuela MT, Jacobs RJ, Arteaga O, et al. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005; 23 (32): 4110-9
59. Van Doorslaer E, Tormans G, Van DP. Cost-effectiveness analysis of vaccination against hepatitis A in travellers. J Med Virol 1994; 44 (4): 463-9
60. Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg 1985 Jun; 94 (3): 365-436
61. Ukkonen P, von Bonsdorff CH. Rubella immunity and morbidity: effects of vaccination in Finland. Scand J Infect Dis 1988; 20 (3): 255-9
62. Muench H. Catalytic models in epidemiology. Cambridge (MA): Harvard University Press, 1959
63. Mutsch M, Spicher VM, Gut C, et al. Hepatitis infection in travellers 1988-2004. Clin Infect Dis 2006 Feb 15; 42 (4): 490-7
64. Berge JJ, Drennan DP, Jacobs RJ, et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000 Feb; 31 (2): 469-73
65. Anonychuk A, Krahn M, Gilca V, et al. The cost of hepatitis A in Canada: ministry and societal perspectives [abstract]. Society for Medical Decision Making Conference; 2006 Oct 14-18; Boston [online]. Available from URL: http://smdm.confex.com/smdm/2006ma/techprogram/P3122.htm [Accessed 2007 Oct 1]
66. Tricco AC, Pham B, Duval B, et al. A review of interventions triggered by hepatitis A infected food-handlers in Canada. BMC Health Serv Res 2006; 6: 157
67. Dalton CB, Haddix A, Hoffman RE, et al. The cost of a foodborne outbreak of hepatitis A in Denver, Colo. Arch Intern Med 1996 May 13; 156 (9): 1013-6
68. Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
69. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996 Oct 16; 276 (15): 1253-8
70. Song F, Eastwood AJ, Gilbody S, et al. Publication and related biases. Health Technol Assess 2000; 4: 1-115
71. Dickersin K. Publication bias: recognizing the problem, understanding its origins and scope, and preventing harm. In: Rothstein H, Sutton AJ, Borenstein M, editors. Publication bias in meta-analysis: prevention, assessment and adjustments. Chichester: John Wiley & Sons Ltd, 2005
72. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 2000; 263: 1385-9